CA2350127A1 - Vecteur de variole aviaire codant un antigene de vih et une cytokine - Google Patents

Vecteur de variole aviaire codant un antigene de vih et une cytokine Download PDF

Info

Publication number
CA2350127A1
CA2350127A1 CA002350127A CA2350127A CA2350127A1 CA 2350127 A1 CA2350127 A1 CA 2350127A1 CA 002350127 A CA002350127 A CA 002350127A CA 2350127 A CA2350127 A CA 2350127A CA 2350127 A1 CA2350127 A1 CA 2350127A1
Authority
CA
Canada
Prior art keywords
hiv
viral construct
mammal
vaccine composition
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002350127A
Other languages
English (en)
Other versions
CA2350127C (fr
Inventor
Stephen Kent
Ian Allister Ramshaw
David Bernard Boyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virax Development Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2350127A1 publication Critical patent/CA2350127A1/fr
Application granted granted Critical
Publication of CA2350127C publication Critical patent/CA2350127C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à un virus de variole aviaire codant un antigène de VIH (gag et/ou pol) et une cytokine (interféron .gamma.).
CA2350127A 1998-11-09 1999-11-09 Vecteur de variole aviaire codant un antigene de vih et une cytokine Expired - Fee Related CA2350127C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP7007A AUPP700798A0 (en) 1998-11-09 1998-11-09 Recombinant viral constructs and methods relating thereto
AUPP7007 1998-11-09
PCT/AU1999/000989 WO2000028003A1 (fr) 1998-11-09 1999-11-09 Vecteur de variole aviaire codant un antigene de vih et une cytokine

Publications (2)

Publication Number Publication Date
CA2350127A1 true CA2350127A1 (fr) 2000-05-18
CA2350127C CA2350127C (fr) 2011-01-04

Family

ID=3811220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2350127A Expired - Fee Related CA2350127C (fr) 1998-11-09 1999-11-09 Vecteur de variole aviaire codant un antigene de vih et une cytokine

Country Status (10)

Country Link
US (1) US7276242B1 (fr)
EP (1) EP1129177B1 (fr)
JP (2) JP4596647B2 (fr)
AT (1) ATE382684T1 (fr)
AU (1) AUPP700798A0 (fr)
CA (1) CA2350127C (fr)
DE (1) DE69937900T2 (fr)
HK (1) HK1040417B (fr)
NZ (1) NZ511567A (fr)
WO (1) WO2000028003A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
EP2302059A1 (fr) * 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications des protéines Env, Gag et Pol du VIH augmentent l'action immunogénique de vaccins génétiques.
WO2002102404A1 (fr) * 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Utilisations de cytokines
AU2004281298B2 (en) * 2003-10-15 2010-05-13 Virax Development Pty Ltd Poxvirus vector encoding retrovirus (eg HIV) and cytokine
EP1673458A4 (fr) * 2003-10-15 2007-12-12 Virax Dev Pty Ltd Vecteur de poxvirus codant un retrovirus tel que le vih et une cytokine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5866136A (en) * 1986-08-01 1999-02-02 Commonwealth Scientific And Industrial Organisation Recombinant vaccine
EP0275300B1 (fr) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Vaccin recombinant
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
ATE241696T1 (de) * 1991-06-14 2003-06-15 Virogenetics Corp Rekombinanter hiv-spezifischer impfstoff aus poxviru

Also Published As

Publication number Publication date
EP1129177B1 (fr) 2008-01-02
US7276242B1 (en) 2007-10-02
DE69937900T2 (de) 2009-01-02
JP2002529076A (ja) 2002-09-10
HK1040417B (zh) 2008-07-18
DE69937900D1 (de) 2008-02-14
HK1040417A1 (en) 2002-06-07
AUPP700798A0 (en) 1998-12-03
WO2000028003A1 (fr) 2000-05-18
JP2010279361A (ja) 2010-12-16
ATE382684T1 (de) 2008-01-15
CA2350127C (fr) 2011-01-04
NZ511567A (en) 2003-09-26
EP1129177A1 (fr) 2001-09-05
JP4596647B2 (ja) 2010-12-08
EP1129177A4 (fr) 2005-04-13

Similar Documents

Publication Publication Date Title
CA2224257A1 (fr) Poxvirus recombines du raton laveur et leur utilisation en tant que vaccin efficace contre l'infection par le virus de l'immunodeficience feline
EP1745798A2 (fr) Compositions de vaccin vhc
CY1107818T1 (el) Hiv-1 tat, ή παραγωγα αυτου για προφυλακτικο και θεραπευτικο εμβολιασμο
WO2001068117A3 (fr) Methodes permettant de reduire l'infection par papillomavirus au moyen de sequences polynucleotidiques imunomodulatoires
CA2596274A1 (fr) Virus mva recombinants et leur utilisation
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
BR0008135A (pt) Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
DK0495896T3 (da) Vaccine til beskyttelse mod HIV-virusinfektioner, fremgangsmåde til fremstilling heraf og anvendelse heraf som diagnostisk middel og immunterapeutisk middel
RU2007115549A (ru) Вакцины на основе инактивированного цельного вируса совместимого субтипа для лечения пациентов с вич-инфекцией
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
WO2005028496A3 (fr) Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
JP2006502228A5 (fr)
HK141594A (en) Peptide fragments of HIV and their use in vaccines and diagnosis
CA2350127A1 (fr) Vecteur de variole aviaire codant un antigene de vih et une cytokine
WO2003061602A3 (fr) Therapie combinee pour le traitement d'infection vih
BR9508629A (pt) Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica
WO2007137591A8 (fr) Vaccin contre le vih
BR0207899A (pt) Imunógeno de combinação para administração sequencial dos componentes para evocar uma resposta imune contra o papilomavìrus, produto farmacêutico, uso de um produto farmacêutico, e, método para evocar uma resposta imune contra o papilomavìrus em um paciente
Marx The Slow, Insidious Natures of the HTLV's: The scope of the viruses that cause AIDS and certain leukemias and lymphomas is broadening in terms of number of people affected and range of clinical syndromes
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
DK0797660T3 (da) Human-immunodefekt-virus-vacciner og terapeutiske midler indeholdende replikations-svækkede HIV-1 NEF deletions-mutanter
JPH07505613A (ja) 免疫不全ウイルスに対するワクチンとしての主要組織適合遺伝子複合体クラス２抗原
WO2003073984A3 (fr) La proteine tat en tant qu'immunogene
WO2002026253A1 (fr) Vaccin contre le sida, son procede de preparation et ses applications

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20121109